A new diagnostic method that ascertains if a person is suffering from Parkinson’s disease or dementia by looking at the manner of walking has been patented.
A new diagnostic technique developed by a St. Mary's Hospital research team in Uijeongbu has been patented and put up for patent registration, which analyses data from an individual's shoes to detect neurological disorders.
Most degenerative brain disorders, such as Parkinson's disease, dementia, and Lou Gehrig's disease, occur at an older age.
Currently, a costly MRI or a PET scan is required for such diagnosis, as well as frequent visits to the hospital.
The new approach, on the other hand, employs a "smart insole" that is placed inside a shoe and collects data from its sensors, which is then analyzed to assess the brain health of the wearer.
The new technique achieved an accuracy of 98.1 percent for the diagnosis of Parkinson's disease, as well as 83.2 percent for differentiating whether an illness is vascular or degenerative.


Dollar Slides to Five-Week Low as Asian Stocks Struggle and Markets Bet on Fed Rate Cut
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand
Asian Markets Stabilize as Wall Street Rebounds and Rate Concerns Ease
European Oil & Gas Stocks Face 2026 With Cautious Outlook Amid Valuation Pressure
Tabletop particle accelerator could transform medicine and materials science
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
BOJ Faces Pressure for Clarity, but Neutral Rate Estimates Likely to Stay Vague
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
China’s Services Sector Posts Slowest Growth in Five Months as Demand Softens
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions
IMF Deputy Dan Katz Visits China as Key Economic Review Nears
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 



